• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconEli Lilly

Eli Lilly

Page 2 of 7
Semaglutide medications Wegovy and Ozempic are pictured
Health
Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers
By Bloomberg, Madison Muller, Ike Swetlitz and Naomi KresgeFebruary 21, 2025
United States President Donald J. Trump speaks at the Friends of Ireland luncheon hosted by United States Speaker of the House of Representatives Paul Ryan, Republican of Wisconsin, at the United States Capitol March 15, 2018 in Washington, DC.
Finance
Weight-loss drug Zepbound helped drive Ireland to $76 billion in goods exports to the U.S. last year—a bittersweet reminder of the challenges ahead
By Ryan HoggFebruary 19, 2025
A woman injects herself with medication.
Health
Ozempic, Wegovy maker calls out Hims & Hers Super Bowl ad: ‘Check before you inject’
By Lindsey LeakeFebruary 11, 2025
A young woman undergoes a brain scan.
Health
Meet the 24-year-old helping Lilly test a preventive Alzheimer’s drug
By Lindsey LeakeFebruary 6, 2025
Karsten Munk Knudsen, chief financial officer of Novo Nordisk A/S, at the company's headquarters in Bagsvaerd, Denmark, on Tuesday, Nov. 26, 2024.
Health
As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs
By Ryan HoggFebruary 5, 2025
A person stands on a scale.
Health
Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs
By Lindsey LeakeFebruary 3, 2025
The increase in online searches for obesity management drugs in recent years correlated to a surge in dispensed prescriptions, according to a new study from the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease.
Health
Online searches predicted the surge in prescriptions of weight-loss drugs like Wegovy and Zepbound, study says. Here’s what could happen next
By Lindsey LeakeJanuary 29, 2025
Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.
Health
Hate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says
By Lindsey LeakeJanuary 21, 2025
Arianna Huffington
Newsletters
Exclusive: Arianna Huffington’s Thrive Global inks novel partnership with pharma giant Eli Lilly
By Alexa Mikhail and Nina AjemianJanuary 9, 2025
Elon Musk admits he takes an Ozempic-like weight-loss drug that RFK Jr. wants to restrict
Health
Elon Musk admits he takes an Ozempic-like weight-loss drug that RFK Jr. wants to restrict
By Alexa MikhailDecember 27, 2024
Novo Nordisk advertising flags and logo on facade, Danish pharmaceutical healthcare giant Novo Nordisk AS, production innovative drugs, obesity treatment Ozempic, Mainz, Germany June 15, 2024
Health
Novo Nordisk faces stock market bloodbath after weight-loss drug trial disappoints
By Ryan Hogg and AFPDecember 20, 2024
Close-up of a patient administering a dose of Zepbound (tirzepatide)
Health
Zepbound vs. Wegovy: New clinical trial says this weight-loss medication sheds more pounds
By Lindsey LeakeDecember 4, 2024
Novo Nordisk’s Wegovy sales jump on international rollouts
Retail
Novo Nordisk’s Wegovy sales jump on international rollouts
By Naomi Kresge and BloombergNovember 6, 2024
Alphabet CEO Sundar Pichai moves his hands as he talks during an interview
Finance
Over 25% of Google’s code is now written by AI—and CEO Sundar Pichai says it’s just the start
By Greg McKennaOctober 30, 2024
Despite the ubiquitousness of injectable GLP-1 drugs indicated for people with obesity, most Americans wouldn’t take them, according to a September 2024 survey from the Physicians Committee for Responsible Medicine.
Health
Most Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey says
By Lindsey LeakeOctober 10, 2024
1
  • 1
  • 2
  • 3
  • 4
  • 5
...7
Most Popular
Big Tech
As Big Tech showers employees with perks to win the talent war, Nvidia built a nearly $5 trillion company by making people pay for their own lunchplaceholder alt text
By Marco Quiroz-GutierrezJuly 1, 2026
Success
MacKenzie Scott alone accounted for one-third of America's $19.2 billion in megagifts last yearplaceholder alt text
By Sydney LakeJune 25, 2026
Personal Finance
Current price of oil as of July 1, 2026placeholder alt text
By Joseph HostetlerJuly 1, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.